# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

B-Cell Lymphomas

Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 61-70 of 564 results.
A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Status: Not yet recruiting
Last Changed: Jun 22, 2020
First Received: Jun 22, 2020
Disease(s): Relapsed/Refractory Diffuse Large B-cell Lymphoma
Intervention(s): Selinexor (combination therapy), Selinexor (combination therapy), Selinexor (combination therapy), Placebo matching for Selinexor (combination therapy), Rituximab (combination therapy), Rituximab (combination therapy), Gemcitabine (combination therapy), Dexamethasone (combination therapy), Cisplatin (combination therapy), Selinexor (continuous therapy), Placebo matching for Selinexor (continuous therapy)
A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Status: Recruiting
Last Changed: Jul 02, 2020
First Received: Jun 20, 2019
Disease(s): Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Intervention(s): ATG-010 60 mg, orally, twice weekly, each 4 week (28-day) a cycle
Locations: Beijing Cancer Hospital, Beijing, Beijing, China
Zanubrutinib, in Combination With Lenalidomide, With or Without Rituximab in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Status: Not yet recruiting
Last Changed: Jun 22, 2020
First Received: Jun 17, 2020
Disease(s): Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Intervention(s): Zanubrutinib, Lenalidomide, Rituximab
A Phase I/II Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Status: Recruiting
Last Changed: Mar 21, 2019
First Received: Nov 06, 2016
Disease(s): Diffuse Large B-cell Lymphoma (DLBCL)
Intervention(s): L19-IL2 - Ph I, L19-IL2 at RD - Ph II, Rituximab
Locations: Münster University Hospital, Münster, Germany
Tumor-Specific Clonotype, Metabolic Profile, and PET/CT in Predicting Chemotherapy Response in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Status: Recruiting
Last Changed: Apr 15, 2020
First Received: Apr 01, 2015
Disease(s): Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
Intervention(s): Chemotherapy, Computed Tomography, Fludeoxyglucose F-18, Positron Emission Tomography
Locations: M D Anderson Cancer Center, Houston, Texas, United States
Clinical Trial to Evaluate CD19 CAR T (CT032) in Patients With Relapsed and/or Refractory Non-Hodgkin's B Cell Lymphoma
Status: Recruiting
Last Changed: Oct 01, 2019
First Received: Jun 21, 2019
Disease(s): Refractory B-Cell Non-Hodgkin Lymphoma, Relapsed B-cell Non-Hodgkin Lymphoma
Intervention(s): CAR-CD19 T Cells
Locations: Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China
First Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang, China
Duvelisib Maintenance After Autologous Stem Cell Transplant in T-Cell and Indolent B-Cell Lymphomas
Status: Not yet recruiting
Last Changed: Apr 02, 2020
First Received: Apr 02, 2020
Disease(s): T-Cell Lymphoma, Indolent B-Cell Lymphoma
Intervention(s): Duvelisib, Peripheral blood draw
Locations: Washington University School of Medicine, Saint Louis, Missouri, United States
Autologous TAC T Cells Targeting CD19 in R/R Large B-Cell Lymphoma
Status: Not yet recruiting
Last Changed: Mar 27, 2020
First Received: Mar 19, 2019
Disease(s): Lymphoma, B-Cell
Intervention(s): TAC01-CD19
Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Status: Recruiting
Last Changed: Jul 09, 2020
First Received: May 13, 2015
Disease(s): Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type
Intervention(s): Autologous Bone Marrow Transplantation, Autologous Hematopoietic Stem Cell Transplantation, Carmustine, Cyclophosphamide, Cytarabine, Etoposide, Ibrutinib, Laboratory Biomarker Analysis, Melphalan, Pharmacogenomic Study, Placebo Administration
Locations: Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States
Anchorage Radiation Therapy Center, Anchorage, Alaska, United States
Alaska Breast Care and Surgery LLC, Anchorage, Alaska, United States
Alaska Oncology and Hematology LLC, Anchorage, Alaska, United States
Alaska Women's Cancer Care, Anchorage, Alaska, United States
... and 269 other locations.
Study of the Safety, Tolerability and Pharmacokinetics of HZ-A-018 in Patients With B Cell Lymphoma
Status: Recruiting
Last Changed: Nov 22, 2019
First Received: Nov 22, 2019
Disease(s): Lymphoma, B-Cell
Intervention(s): HZ-A-018
Locations: First Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang, China